Mike Kratky
Stock Analyst at Leerink Partners
(2.66)
# 1,971
Out of 5,142 analysts
40
Total ratings
43.48%
Success rate
25.97%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $386 → $360 | $249.38 | +44.36% | 2 | Feb 19, 2026 | |
| TXG 10x Genomics | Maintains: Market Perform | $22 → $20 | $18.89 | +5.88% | 5 | Jan 27, 2026 | |
| PEN Penumbra | Downgrades: Market Perform | $374 | $339.20 | +10.26% | 2 | Jan 16, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $74.37 | +72.11% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $58.29 | +66.41% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $98.61 | +11.55% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $13.76 | +103.49% | 1 | Feb 24, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $73.26 | +18.76% | 2 | Oct 25, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $28.26 | +59.24% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $14.56 | +51.10% | 1 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $38.25 | +9.80% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $492.10 | -30.50% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $82.44 | -9.02% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $27.36 | +35.23% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $35.38 | -74.56% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $29.66 | +68.58% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.23 | +3,558.54% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $437.79 | -28.05% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $88.43 | -64.94% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $27.20 | -48.53% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $28.07 | +42.50% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $57.93 | +562.87% | 1 | Aug 11, 2022 |
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $386 → $360
Current: $249.38
Upside: +44.36%
10x Genomics
Jan 27, 2026
Maintains: Market Perform
Price Target: $22 → $20
Current: $18.89
Upside: +5.88%
Penumbra
Jan 16, 2026
Downgrades: Market Perform
Price Target: $374
Current: $339.20
Upside: +10.26%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $74.37
Upside: +72.11%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $58.29
Upside: +66.41%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $98.61
Upside: +11.55%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $13.76
Upside: +103.49%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $73.26
Upside: +18.76%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $28.26
Upside: +59.24%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $14.56
Upside: +51.10%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $38.25
Upside: +9.80%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $492.10
Upside: -30.50%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $82.44
Upside: -9.02%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $27.36
Upside: +35.23%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $35.38
Upside: -74.56%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $29.66
Upside: +68.58%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.23
Upside: +3,558.54%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $437.79
Upside: -28.05%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $88.43
Upside: -64.94%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $27.20
Upside: -48.53%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $28.07
Upside: +42.50%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $57.93
Upside: +562.87%